Anna Asloyan
Family Medicine · Brooklyn, NYNPI 1225022445
Payments from drug & device makers
Across 202 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$964
- Lilly USA, LLC$300
- E.r. Squibb & Sons, L.L.C.$286
- Boehringer Ingelheim$220
- Pfizer$158
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,450100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $1,352 |
| Amgen(2 entities) | 41 | $964 |
| Lilly USA, LLC | 13 | $300 |
| E.r. Squibb & Sons, L.L.C. | 13 | $286 |
| Boehringer Ingelheim | 9 | $220 |
| Pfizer | 8 | $158 |
| Amarin Pharma, Inc. | 8 | $152 |
| Merck | 10 | $147 |
| GSK | 6 | $135 |
| Nestle Healthcare Nutrition Inc. | 8 | $134 |
| Novo Nordisk | 5 | $111 |
| AstraZeneca | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73 |
| Novartis | 3 | $65 |
| Endo Pharmaceuticals Inc. | 3 | $60 |
| Johnson & Johnson | 2 | $60 |
| Phathom Pharmaceuticals, Inc. | 2 | $50 |
| Genentech USA, Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$115
How this compares
$4,450 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 112 | $111,160 |
| LinzessLinaclotide | 177 | $97,859 |
| FarxigaDapagliflozin Propanediol | 151 | $90,128 |
| TrulicityDulaglutide | 82 | $86,408 |
| JanumetSitagliptin Phos/Metformin Hcl | 129 | $81,359 |
| JanuviaSitagliptin Phosphate | 127 | $77,828 |
| VascepaIcosapent Ethyl | 179 | $67,642 |
| Diclofenac Sodium | 162 | $66,166 |
| JardianceEmpagliflozin | 93 | $65,573 |
| EliquisApixaban | 96 | $63,990 |
| MounjaroTirzepatide | 56 | $57,593 |
| Repatha SureclickEvolocumab | 105 | $54,011 |
| OzempicSemaglutide | 55 | $49,340 |
| CreonLipase/Protease/Amylase | 59 | $49,170 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 64 | $35,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $147 | $195,059320 claims |
| AbbVieLinzess, Creon, Restasis, Synthroid | $1,352 | $171,756453 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $300 | $144,001138 claims |
| Aimmune Therapeutics, Inc.Zenpep | $22 | $111,160112 claims |
| AstraZenecaFarxiga, Crestor, Brilinta | $83 | $102,566188 claims |
| Boehringer IngelheimJardiance, Jentadueto | $220 | $73,416109 claims |
| Novo NordiskOzempic, Rybelsus | $111 | $65,91566 claims |
| PfizerEliquis | $158 | $63,99096 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $135 | $26,36845 claims |
| Johnson & JohnsonXarelto | $60 | $24,27738 claims |
| NovartisEntresto | $65 | $21,20233 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $20,70447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Michael YuryevBrooklyn$589K
- Matthew SpitzerBrooklyn$469K
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.